Xeris Biopharma (NASDAQ:XERS) Hits New 12-Month High - What's Next?
Lundbeck is working with advisers as Xeris reported $91 million in second-quarter revenue on demand for Recorlev, Bloomberg said.
6 Articles
6 Articles
Lundbeck expresses interest in buying Xeris, Bloomberg News reports - Regional Media News
Sept 29 (Reuters) - Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma, Bloomberg News reported on Tuesday, citing people familiar with the matter. Lundbeck has been working with advisers to explore a takeover of Xeris, according to the report. Lundbeck [...]
Lundbeck expresses interest in buying Xeris, Bloomberg News reports
Sept 29 (Reuters) - Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma, Bloomberg News reported on Tuesday, citing people familiar with the matter. Lundbeck has been working with advisers to explore a ta...
Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $250,000.00 in Stock
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction dated Monday, September 28th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 1,614,208 shares in the company, valued at $16,142,080. This represents a 1.53% decrease in their position. The transact…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
